Published: Fri, February 22, 2019
Medicine | By Tracy Klein

FDA Warns Against Blood Transfusions From Young Donors as Anti-Aging Treatment

FDA Warns Against Blood Transfusions From Young Donors as Anti-Aging Treatment

"Simply put, we're concerned that some patients are being preyed upon by unscrupulous actors touting treatments of plasma from young donors as cures and remedies", the FDA said in its warning.

A government website lists a clinical trial sponsored by Ambrosia that included 200 people who received young donor plasma treatments. A report by The Verge cites a Monterey, California-based company called Ambrosia that takes "intravenous infusions of plasma from young donors, who are in the age range of 16 to 25". According to Gottlieb, young blood infusions are particularly risky because they involve the transmission of large volumes of blood, which in turn heightens the risk of adverse side effects. According to a statement published by the FDA today, establishments in multiple states are promoting plasma infusions from young donors as a supposed treatment for aging, Alzheimer's disease, Parkinson's, PTSD, heart disease, and a number of other conditions. But to date, Gottlieb says, "there is no compelling clinical evidence on its efficacy, nor is there information on appropriate dosing for treatment of the conditions for which these products are being advertised". There's nothing within the FDA's assertion about wholesome methods for unholy, undead Individuals to taper off their consumption of the blood of younger folks, and no sense that anybody within the administration is even contemplating the attainable hurt of forcing them on a crash blood food regimen, not to mention mitigating them.

A startup called Ambrosia claims that it is now offering young-blood transfusions-at a cost of $8,000 for 1 liter of young blood, or $12,000 for 2 liters-in Los Angeles, San Francisco, Houston, Tampa, Fla., and Omaha, Neb., Business Insider reported last month.

On Tuesday, Ambrosia said in a statement on its website that "in compliance" with the FDA statement, it had ceased patient treatments.

The idea of infusing young blood to fight ageing has attracted technology entrepreneurs like billionaire Peter Thiel and was lampooned in a 2017 episode of the HBO show "Silicon Valley".

The officials said none of the plasma treatments has gone through the rigorous testing the agency normally requires.

The agency, he said, is concerned that "unproven purposes could also discourage patients suffering from serious or intractable illnesses from receiving safe and effective treatments that may be available to them", saying that the plasma itself could be harmful.

But the FDA believes that as with many experimental procedures, it's "buyer beware" when it comes to plasma infusions.

But while some of these mouse studies have been encouraging, other studies have been less so. Over the years, rodent experiments have hinted that components of young mouse blood may invigorate older mice, potentially acting as an anti-aging treatment.

Like this: